| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-GD2-like IgM autoreactivity in multiple sclerosis patients
|
Marconi, S
|
|
2006
|
12 |
3 |
p. 302-308
|
artikel
|
| 2 |
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
|
Ford, C C
|
|
2006
|
12 |
3 |
p. 309-320
|
artikel
|
| 3 |
Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire
|
van Noort, J M
|
|
2006
|
12 |
3 |
p. 287-293
|
artikel
|
| 4 |
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis
|
Fainardi, E
|
|
2006
|
12 |
3 |
p. 294-301
|
artikel
|
| 5 |
Cognitive and motor function in people with multiple sclerosis in Stockholm County
|
Einarsson, U
|
|
2006
|
12 |
3 |
p. 340-353
|
artikel
|
| 6 |
Fatal accidents among Danes with multiple sclerosis
|
Brønnum-Hansen, Henrik
|
|
2006
|
12 |
3 |
p. 329-332
|
artikel
|
| 7 |
Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey
|
Sorensen, Per Soelberg
|
|
2006
|
12 |
3 |
p. 253-264
|
artikel
|
| 8 |
Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS)
|
Gottesman, M H
|
|
2006
|
12 |
3 |
p. 271-280
|
artikel
|
| 9 |
Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue
|
Lebrun, C
|
|
2006
|
12 |
3 |
p. 321-324
|
artikel
|
| 10 |
Multiple sclerosis-associated retrovirus and optic neuritis
|
Sotgiu, S
|
|
2006
|
12 |
3 |
p. 357-359
|
artikel
|
| 11 |
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
|
Polman, Chris H
|
|
2006
|
12 |
3 |
p. 245-246
|
artikel
|
| 12 |
No association of CCR5D32 gene mutation with multiple sclerosis in Croatian and Slovenian patients
|
Ristić, Smiljana
|
|
2006
|
12 |
3 |
p. 360-362
|
artikel
|
| 13 |
Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis
|
Petersen, Bodil
|
|
2006
|
12 |
3 |
p. 247-252
|
artikel
|
| 14 |
Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria
|
Portaccio, E
|
|
2006
|
12 |
3 |
p. 281-286
|
artikel
|
| 15 |
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis
|
Putzki, Norman
|
|
2006
|
12 |
3 |
p. 363-366
|
artikel
|
| 16 |
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
|
Guimarães, J
|
|
2006
|
12 |
3 |
p. 354-356
|
artikel
|
| 17 |
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
|
Petzold, A
|
|
2006
|
12 |
3 |
p. 325-328
|
artikel
|
| 18 |
The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients
|
Rajda, C
|
|
2006
|
12 |
3 |
p. 265-270
|
artikel
|
| 19 |
The relation between menarche and the age of first symptoms in a multiple sclerosis cohort
|
Sloka, J S
|
|
2006
|
12 |
3 |
p. 333-339
|
artikel
|
Tijdschrift beschrijving